Document is current
Any future updates will be listed below
-
Authors
Chng, Wee-Joo https://orcid.org/0000-0003-2578-8335
Lonial, Sagar https://orcid.org/0000-0002-8322-9323
Morgan, Gareth J.
Iida, Shinsuke
Moreau, Philippe
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
Twumasi-Ankrah, Philip
Villarreal, Miguel
Dash, Ajeeta B. https://orcid.org/0000-0001-5714-8354
Vorog, Alexander
Zhang, Xiaoquan
Suryanarayan, Kaveri
Labotka, Richard
Dimopoulos, Meletios A. https://orcid.org/0000-0001-8990-3254
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
-
Funding
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
- License Information
-
More Information
Article History
Received: 2 September 2022
Revised: 2 December 2022
Accepted: 2 December 2022
First Online: 12 January 2023
Competing interests
: W-JC: Honoraria: Johnson and Johnson, BMS/Celgene, Amgen, Takeda, AbbVie, Sanofi, Pfizer; Research funding: Johnson and Johnson, BMS/Celgene, NMRC Singapore Translational Research (STaR) Investigator Award, National Research Foundation Singapore, Singapore Ministry of Education under the Research Centers of Excellence initiative. SL: Consultancy: Janssen, BMS, Celgene, Amgen, GSK, AbbVie, Takeda, Novartis, Genentech; Research support for trials: Janssen, BMS, Novartis; Member on board of directors and holder of stock: TG Therapeutics. GJM: Advisory council or committee: Celgene, BMS, Sanofi, Karyopharm, Janssen, GSK, Amgen, Oncopeptides, AbbVie. SI: Research funding: BMS, Ono, Takeda, Janssen, AbbVie, Chugai, Celgene, Sanofi, Pfizer, Daiichi Sankyo; Honoraria: Ono, Takeda, Janssen, BMS, Sanofi. PM: Honoraria: AbbVie, Amgen, Janssen, Sanofi, Celgene. SKK: Research funding: AbbVie, Takeda, Janssen, KITE, Merck, MedImmune/AstraZeneca, Novartis, Roche, Celgene, Adaptive, Sanofi; Advisory council or committee: KITE, Janssen, Takeda, MedImmune/AstraZeneca, AbbVie, Celgene, Adaptive. PT-A, MV, XZ: Employee: Takeda. ABD, AV, RL: Employee and holder of stock options: Takeda. KS: Employee, equity holder and divested equity in the past 24 months: Takeda. MAD: Honoraria: Amgen, BMS, Takeda, Beigene, Janssen. SVR: None.
